Document is current
Any future updates will be listed below
-
Authors
Brunet, Lisa
Alexandre, David https://orcid.org/0000-0003-4811-0818
Lee, Jiyoung
Blanquer-Rosselló, Maria del Mar https://orcid.org/0000-0002-4753-2261
Bracquemond, David
Guernet, Alexis
Chhouri, Houssein
Goupil, Mathilde
Kherrouche, Zoulika
Arabo, Arnaud https://orcid.org/0000-0002-3012-3621
Mancini, Maicol https://orcid.org/0000-0002-7472-0786
Cartier, Dorthe
Yao, Shen
Godefroy, David
Dehedin, Julie
Li, Jian-Rong
Duparc, Céline https://orcid.org/0000-0002-7301-6287
Jamme, Philippe
Vinchent, Audrey
Bérard, Caroline
Tulasne, David
Arena, Sabrina https://orcid.org/0000-0002-1318-2494
Bardelli, Alberto https://orcid.org/0000-0003-1647-5070
Cheng, Chao https://orcid.org/0000-0002-5002-3417
Cho, Byoung Chul https://orcid.org/0000-0002-5562-270X
Wurtz, Olivier
Coulouarn, Cédric https://orcid.org/0000-0002-5692-9586
Maraver, Antonio https://orcid.org/0000-0002-5527-5680
Aaronson, Stuart A. https://orcid.org/0000-0002-4643-0474
Cortot, Alexis B.
Anouar, Youssef https://orcid.org/0000-0002-4684-5135
Grumolato, Luca https://orcid.org/0000-0001-8231-3032
-
Funding
Funding for this research was provided by:
Institut National Du Cancer (PLBIO 2017-159)
Agence Nationale de la Recherche (METROPOLIS-158530)
Fondation ARC pour la Recherche sur le Cancer (PJA20161205119)
Ligue Contre le Cancer
Institut National de la Santé et de la Recherche Médicale
- License Information
-
More Information
Article History
Received: 9 August 2023
Accepted: 1 July 2025
First Online: 22 August 2025
Competing interests
: Z.K. reports financial support from DeuterOncology NV outside the submitted work. B.C.C. reports stock ownership with TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus Therapeutics, Interpark Bio Convergence Corp and J INTS BIO; reports participating in an advisory role for KANAPH Therapeutic Inc, Brigebio Therapeutics, Cyrus Therapeutics, Guardant Health and Oscotec; has received consulting fees from Novartis, Abion, BeiGene, AstraZeneca, Boehringer-Ingelheim, Roche, Bristol-Myers Squibb, ONO, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD, Janssen, Medpacto, and Blueprint medicines; has received grants or funds from Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, ONO, Dizal Pharma, MSD, Abbvie, Medpacto, GI Innovation, Eli Lilly, Blueprint medicines, and Interpark Bio Convergence Corp; has received royalties from Campions Oncology, Crown Bioscience and Imagen; and is the founder of DAAN Biotherapeutics. A.B.C. has received honorarium for advisory positions, board memberships, lectures, or non-financial support from the following sources: Astra-Zeneca, Roche, MSD, Pfizer, Novartis, Takeda, Janssen, AbbVie, and Amgen. L.G. is inventor of a patent on DNA barcoding issued to Inserm and University of Rouen (WO2017068120A1). S. A. reports personal fees from MSD Italia and a patent (Italian patent application No. 102022000007535) outside the submitted work. A.B. reports receipt of grants/research supports from Neophore, AstraZeneca, Boehringer Ingelheim, and honoraria/consultation fees from Guardant Health. A.B. is stock shareholder of Neophore and Kither Biotech. A.B. is advisory boards member for Neophore. The remaining authors declare no competing interests.
